NASDAQ:NEPH

Nephros - NEPH Stock Forecast, Price & News

$0.91

-0.04 (-4.21%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.91
▼
$0.97
50-Day Range: $0.91
▼
$1.87
52-Week Range: $0.91
▼
$8.51

Volume: 11,590 shs
Average Volume: 58,695 shs
Market Capitalization: $9.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.63

Nephros MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 1,067.6% Upside
$10.63 Price Target
Short Interest: Healthy
0.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.18
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.50) to ($0.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Nephros has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.63, Nephros has a forecasted upside of 1,067.6% from its current price of $0.91.
Amount of Analyst Coverage
Nephros has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.28% of the float of Nephros has been sold short.
Short Interest Ratio / Days to Cover
Nephros has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nephros has recently decreased by 52.26%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Nephros does not currently pay a dividend.
Dividend Growth
Nephros does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NEPH.

3.4

News and Social Media Coverage

News Sentiment
Nephros has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Nephros this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for NEPH on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nephros insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.60% of the stock of Nephros is held by insiders.
Percentage Held by Institutions
41.59% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nephros are expected to grow in the coming year, from ($0.50) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nephros is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nephros is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nephros has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nephros (NASDAQ:NEPH) Stock

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

NEPH Stock News Headlines

September 28, 2022 | seekingalpha.com

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

September 28, 2022 | finance.yahoo.com

Nephros Partners with Donastar and Tractor Beverage Company to Supply and Service Nationwide Fast-Casual Restaurant Operation

September 8, 2022 | finance.yahoo.com

Nephros Appoints Joe Harris to Its Board of Directors

August 13, 2022 | finance.yahoo.com

Nephros, Inc. (NASDAQ:NEPH) Just Reported Earnings, And Analysts Cut Their Target Price

August 12, 2022 | investing.com

Nephros, Inc. Tops Q2 EPS by 2c

August 12, 2022 | benzinga.com

Nephros: Q2 Earnings Insights

August 10, 2022 | seekingalpha.com

Nephros, Inc.'s (NEPH) CEO Andy Astor on Q2 2022 Results - Earnings Call Transcript

August 10, 2022 | nasdaq.com

Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates

August 10, 2022 | finance.yahoo.com

Nephros Announces Results for Quarter Ended June 30, 2022

July 27, 2022 | finance.yahoo.com

Nephros Second Quarter 2022 Financial Results Conference Call

July 6, 2022 | finance.yahoo.com

Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months

May 17, 2022 | seekingalpha.com

Nephros' HDF assist module gets FDA nod for hemodiafiltration therapy for kidney disease patients

May 17, 2022 | finance.yahoo.com

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

May 7, 2022 | seekingalpha.com

Nephros, Inc. (NEPH) CEO Andy Astor on Q1 2022 Results - Earnings Call Transcript

May 4, 2022 | nasdaq.com

Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates

May 4, 2022 | finance.yahoo.com

Nephros Announces Results for Quarter Ended March 31, 2022

April 27, 2022 | finance.yahoo.com

Nephros First Quarter 2022 Financial Results Conference Call

April 26, 2022 | finance.yahoo.com

Nephros Unveils New Branding and Website

March 21, 2022 | tmcnet.com

Nephros to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

March 21, 2022 | finance.yahoo.com

Nephros to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

February 28, 2022 | finance.yahoo.com

Nephros to Present at Q1 Virtual Investor Summit

February 25, 2022 | seekingalpha.com

Nephros reports Q4 results

February 24, 2022 | nasdaq.com

Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates

February 24, 2022 | benzinga.com

Nephros: Q4 Earnings Insights

February 24, 2022 | finance.yahoo.com

Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

NEPH Company Calendar

Last Earnings: 8/10/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NEPH
CUSIP: N/A
CIK: 1196298
Web: www.nephros.com
Phone: (201) 343-5202
Fax: 201-343-5207
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.63
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $5.25
Forecasted Upside/Downside: +1,067.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,110,000.00
Net Margins: -50.68%
Pretax Margin: -50.68%
Return on Equity: -37.94%
Return on Assets: -32.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.27
Quick Ratio: 3.06

Sales & Book Value

Annual Sales: $10.40 million
Price / Sales: 0.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.44 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 10,320,000
Free Float: 9,432,000
Market Cap: $9.39 million
Optionable: Not Optionable
Beta: 1.21

Key Executives

Mr. Andrew Astor (Age 65)
CEO, CFO, Pres & Director
Comp: $378.62k

Mr. Wesley S. Lobo (Age 45)
Chief Commercial Officer
Comp: $395.66k

Ms. Joleen C. Turner
VP of Marketing & Bus. Devel.

Mr. Shane Sullivan
VP of Sales

Vashone R. Thomas
VP of Quality, Regulatory, & HR

Mr. Daron G. Evans (Age 48)
Chief Exec. Officer of Specialty Renal Products, Inc

Mr. Greg Lucas
Pres of Aether Water Systems

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NEPH Stock - Frequently Asked Questions

Should I buy or sell Nephros stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEPH shares.
View NEPH analyst ratings or view top-rated stocks.
What is Nephros' stock price forecast for 2022?: 3 brokerages have issued 1 year price objectives for Nephros' stock. Their NEPH share price forecasts range from $5.25 to $16.00. On average, they predict the company's share price to reach $10.63 in the next year. This suggests a possible upside of 1,067.6% from the stock's current price.
View analysts price targets for NEPH or view top-rated stocks among Wall Street analysts.
How have NEPH shares performed in 2022?: Nephros' stock was trading at $5.90 at the start of the year. Since then, NEPH stock has decreased by 84.6% and is now trading at $0.91.
View the best growth stocks for 2022 here.
When is Nephros' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NEPH earnings forecast.

How were Nephros' earnings last quarter?: Nephros, Inc. (NASDAQ:NEPH) issued its earnings results on Wednesday, August, 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The company had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.70 million. Nephros had a negative net margin of 50.68% and a negative trailing twelve-month return on equity of 37.94%.
What guidance has Nephros issued on next quarter's earnings?: Nephros issued an update on its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.90 million-$2.90 million, compared to the consensus revenue estimate of $2.52 million.
What is Nephros' stock symbol?: Nephros trades on the NASDAQ under the ticker symbol "NEPH."
How do I buy shares of Nephros?: Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nephros' stock price today?: One share of NEPH stock can currently be purchased for approximately $0.91.
How much money does Nephros make?: Nephros (NASDAQ:NEPH) has a market capitalization of $9.39 million and generates $10.40 million in revenue each year. The company earns $-4,110,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
How can I contact Nephros?: Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The official website for the company is www.nephros.com. The company can be reached via phone at (201) 343-5202, via email at ksmith@pcgadvisory.com, or via fax at 201-343-5207.

This page (NASDAQ:NEPH) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nephros - NEPH Stock Forecast, Price & News

Nephros MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month